Abstract 649P
Background
Nectin-4 is a cell adhesion molecule that serves as an attractive therapeutic target for ADCs, due to its high expression in a variety of solid tumors. SHR-A2102 is a novel ADC comprised of a fully humanized IgG1 mAb against nectin-4, a cleavable linker, and a topoisomerase I inhibitor payload. Here we present results of the dose escalation (D-ESC) and dose expansion (D-EXP) parts of a phase 1 study of SHR-A2102 for treating solid tumors.
Methods
Patients (pts) with nectin-4 positive, locally advanced unresectable or metastatic solid tumors, who had failed or were intolerant to standard therapies or had no standard treatment, were given SHR-A2102 intravenously Q3W. Primary objectives were to assess safety and tolerability.
Results
As of Apr 9, 2024, 38 pts were enrolled (median age: 61 yrs; ≥3 lines of prior therapies: 60.5%; prior ICI: 78.9%). During D-ESC, 17 pts received SHR-A2102 at 2 to 10 mg/kg. Only 1 pt in the 10 mg/kg group experienced a DLT (grade 4 decreased platelet count), and MTD was not yet reached. During D-EXP, additional 10 and 11 pts were given SHR-A2102 at 6 and 8 mg/kg, respectively. Overall, grade 3/4 TRAEs occurred in 42.1% (16/38) of pts, with the most common (≥10%) being decreased WBC count (21.1%), anemia (18.4%), decreased neutrophil count (15.8%), and decreased lymphocyte count (13.2%). No treatment-related deaths occurred. Among 30 pts evaluable for tumor response, ORR was 23.3% and DCR was 76.7% (Table). In 16 heavily pretreated NSCLC pts evaluable for tumor response, ORR was 31.3% (non-sq, 50.0%; sq, 12.5%) and DCR was 87.5% (non-sq, 75.0%; sq, 100.0%; Table). Table: 649P
Anti-tumor activity
Non-sq NSCLC (N=8) | Sq NSCLC (N=8) | All NSCLC (N=16) | All tumor types (N=30) | |
Best overall response, n (%) | ||||
PR | 4 (50.0) | 1 (12.5) | 5 (31.3) | 7 (23.3) |
SD | 2 (25.0) | 7 (87.5) | 9 (56.3) | 16 (53.3) |
PD | 2 (25.0) | 0 | 2 (12.5) | 7 (23.3) |
ORR, % (95% CI) | 50.0 (15.7–84.3) | 12.5 (0.3–52.7) | 31.3 (11.0–58.7) | 23.3 (9.9–42.3) |
DCR, % (95% CI) | 75.0 (34.9–96.8) | 100.0 (63.1–100.0) | 87.5 (61.7–98.5) | 76.7 (57.7–90.1) |
Non-sq, non-squamous; sq, squamous.
Conclusions
SHR-A2102 showed a manageable safety profile and promising anti-tumor activity. Indication-specific cohorts are being recruited during the efficacy expansion part.
Clinical trial identification
NCT05701709; Release date: Jan 27, 2023.
Editorial acknowledgement
Legal entity responsible for the study
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
X. Li, Y. Huang, L. Song: Financial Interests, Personal, Full or part-time Employment: Jiangsu Hengrui Pharmaceuticals. All other authors have declared no conflicts of interest.
Resources from the same session
723P - A phase II study of cadonilimab plus chemotherapy in persistent recurrent/ metastatic cervical cancer patients who failed previous immuno/chemotherapy
Presenter: Li Xiaoling Li
Session: Poster session 01
724P - Preliminary outcomes from a phase Ib/II study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer
Presenter: Guiling Li
Session: Poster session 01
725P - Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group
Presenter: Dominik Denschlag
Session: Poster session 01
726P - Efficacy and safety of pembrolizumab plus olaparib combination therapy in recurrent cervical cancer progressed on platinum-based chemotherapy: Results from the phase II trial of GOTIC-025
Presenter: Kosei Hasegawa
Session: Poster session 01
727P - Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China
Presenter: Yang Sun
Session: Poster session 01
Resources:
Abstract
728P - Chemotherapy plus tislelizumab in young patients with cervical cancer preserve fertility: A phase II study
Presenter: Danbo Wang
Session: Poster session 01
729P - Patterns of survivorship care of cervical cancer patients with or without HIV infection in Botswana 2015-2022
Presenter: Sheldon Amoo-Mitchual
Session: Poster session 01
730P - Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA
Presenter: Guillaume Beinse
Session: Poster session 01
731P - Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy
Presenter: Mansoor Raza Mirza
Session: Poster session 01
732P - Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
Presenter: Stephanie Blank
Session: Poster session 01